CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia

CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia

Abstract Ancillary testing with immunohistochemistry has shown recent promise in the workup of equivocal bladder lesions. We read with interest the recent findings of Alston et al., who assessed the diagnostic utility of alpha-methylacyl-CoA racemase (AMACR) in comparison to cytokeratin 20 (CK20) in...

Full description

Bibliographic Details
Main Authors: Daniel J. Neal, Mahul B. Amin, Steven C. Smith
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Diagnostic Pathology
Subjects:
Urothelial carcinoma in situ
Cytokeratin 20
Alpha-methylacyl-CoA racemase
Online Access:http://link.springer.com/article/10.1186/s13000-020-00984-2

Internet

http://link.springer.com/article/10.1186/s13000-020-00984-2

Similar Items